CLOs on the Move

Tmunity

www.tmunity.com

 
Our vision is to become the leading innovative global life-sciences company that unlocks the potential of T-cell biology and combines it with the power of T-cell engineering excellence to provide cures for patients. Through our model of seamless and rapid integration of research, translational medicine, manufacturing science, clinical development and customer-centric approaches, we will design and deliver enhanced state-of-the-art solutions for patients in a host of disease areas using Chimeric Antigen Receptors (CARs), Gene edited T-Cells, T regulatory cells (Treg), and engineered T Cell Receptors (TCRs)
  • Number of Employees: 100-250
  • Annual Revenue: $50-100 Million
  • www.tmunity.com
  • 3020 Market Street Suite 535
    Philadelphia, PA USA 19104
  • Phone: 215.966.1600

Executives

Name Title Contact Details
Chris Arasin
Executive Director, Assistant General Counsel Profile
Moji James
General Counsel Profile
Moji James
Executive Vice President, Chief Legal and Compliance Officer and Corporate Secretary Profile

Similar Companies

54gene

54gene was founded in 2019 by Dr. Abasi Ene-Obong to address the significant gap in the global genomics market; Nearly 90% of genetic material used in pharmaceutical research is Caucasian. Only 2% is African, despite the fact that Africans and people of African ancestry are more genetically diverse than all other world populations combined. As a result, pharmaceutical research and development is lacking the diverse data that may hold the key to medical discoveries and new healthcare solutions.

ChinaPeptides Co.,Ltd

ChinaPeptides Co.,Ltd is a Louisville, KY-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Immunitas Therapeutics

Immunitas Therapeutics is a single cell genomics-based drug discovery company.

Apple Valley Chamber-commerce

Apple Valley Chamber-commerce is a Apple Valley, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.

Constellation Pharmaceuticals

Constellation Pharmaceuticals is a clinical-stage biopharmaceutical company using its expertise in epigenetics to discover and develop novel therapeutics that address serious unmet medical needs in patients with cancers associated with abnormal gene expression. Our integrated epigenetics platform enables us to validate targets and generate small molecules against these targets that selectively modulate gene expression in tumor and immune cells to drive anti-tumor activity. We are able to target a broad variety of epigenetic regulators using our platform and have generated development candidates acting against distinct classes of those regulators.